V
Veronique Minard-Colin
Researcher at Université Paris-Saclay
Publications - 143
Citations - 6129
Veronique Minard-Colin is an academic researcher from Université Paris-Saclay. The author has contributed to research in topics: Rhabdomyosarcoma & Medicine. The author has an hindex of 24, co-authored 107 publications receiving 3826 citations. Previous affiliations of Veronique Minard-Colin include Institut Gustave Roussy & University of Southern California.
Papers
More filters
Journal ArticleDOI
Gut microbiome influences efficacy of PD-1–based immunotherapy against epithelial tumors
Bertrand Routy,Bertrand Routy,Bertrand Routy,Lisa Derosa,Lisa Derosa,Lisa Derosa,Connie P.M. Duong,Connie P.M. Duong,Maryam Tidjani Alou,Maryam Tidjani Alou,Maryam Tidjani Alou,Romain Daillère,Romain Daillère,Romain Daillère,Aurélie Fluckiger,Aurélie Fluckiger,Meriem Messaoudene,Meriem Messaoudene,Conrad Rauber,Conrad Rauber,Conrad Rauber,Maria Paula Roberti,Maria Paula Roberti,Marine Fidelle,Marine Fidelle,Caroline Flament,Caroline Flament,Vichnou Poirier-Colame,Vichnou Poirier-Colame,Paule Opolon,Christophe Klein,Kristina Iribarren,Laura Mondragón,Nicolas Jacquelot,Nicolas Jacquelot,Nicolas Jacquelot,Bo Qu,Bo Qu,Bo Qu,Gladys Ferrere,Gladys Ferrere,Gladys Ferrere,Céline Clémenson,Céline Clémenson,Laura Mezquita,Jordi Remon Masip,C. Naltet,Solenn Brosseau,Coureche Kaderbhai,Corentin Richard,Hira Rizvi,Florence Levenez,Nathalie Galleron,Benoit Quinquis,Nicolas Pons,Bernhard Ryffel,Veronique Minard-Colin,Patrick Gonin,Jean-Charles Soria,Eric Deutsch,Eric Deutsch,Yohann Loriot,Yohann Loriot,François Ghiringhelli,Gérard Zalcman,François Goldwasser,B. Escudier,B. Escudier,Matthew D. Hellmann,Matthew D. Hellmann,Alexander M.M. Eggermont,Alexander M.M. Eggermont,Didier Raoult,Laurence Albiges,Laurence Albiges,Guido Kroemer,Laurence Zitvogel +76 more
TL;DR: It is found that primary resistance to ICIs can be attributed to abnormal gut microbiome composition, and Antibiotics inhibited the clinical benefit of ICIs in patients with advanced cancer.
Journal ArticleDOI
Non-Hodgkin Lymphoma in Children and Adolescents: Progress Through Effective Collaboration, Current Knowledge, and Challenges Ahead
Veronique Minard-Colin,Laurence Brugières,Alfred Reiter,Mitchell S. Cairo,Thomas G. Gross,Wilhelm Woessmann,Birgit Burkhardt,John T. Sandlund,Denise Williams,Marta Pillon,Keizo Horibe,Anne Auperin,Marie-Cécile Le Deley,Martin Zimmerman,Sherrie L. Perkins,Martine Raphael,Laurence Lamant,Wolfram Klapper,Lara Mussolin,Hélène Poirel,Elizabeth Macintyre,Christine Damm-Welk,Angelo Rosolen,Catherine Patte +23 more
TL;DR: Challenges that remain include defining the value of prognostic factors, such as early response on positron emission tomography/computed tomography and minimal disseminated and residual disease, using new biologic technologies to improve risk stratification, and developing innovative therapies, both in the first-line setting and for relapse.
Journal ArticleDOI
Crizotinib-induced immunogenic cell death in non-small cell lung cancer
Peng Liu,Liwei Zhao,Jonathan Pol,Sarah Levesque,Adriana Petrazzuolo,Christina Pfirschke,Camilla Engblom,Steffen Rickelt,Takahiro Yamazaki,Kristina Iribarren,Laura Senovilla,Lucillia Bezu,Erika Vacchelli,Valentina Sica,Andréa Melis,Tiffany Martin,Lin Xia,Heng Yang,Qingqing Li,Jinfeng Chen,Sylvère Durand,Fanny Aprahamian,Deborah Lefevre,Sophie Broutin,Angelo Paci,Angelo Paci,Amaury Bongers,Veronique Minard-Colin,Eric Tartour,Laurence Zitvogel,Lionel Apetoh,Yuting Ma,Mikael J. Pittet,Oliver Kepp,Guido Kroemer +34 more
TL;DR: It is shown that crizotinib is an effective stimulator of immunogenic cell death and can potentiate the efficacy of immune checkpoint blockade and can exert their anticancer effect through indirect immune-dependent mechanism.
Journal ArticleDOI
Vemurafenib in Pediatric Patients With BRAFV600E Mutated High-Grade Gliomas
Francisco Bautista,Angelo Paci,Veronique Minard-Colin,Christelle Dufour,Jacques Grill,Ludovic Lacroix,Pascale Varlet,Dominique Valteau-Couanet,Birgit Geoerger +8 more
TL;DR: It is suggested that BRAFV600 is an oncogenic driver in pediatric gliomas and pharmacokinetic studies suggest that maximum concentration and exposure of vemurafenib at steady‐state is dose‐dependent and similar in children to that reported in adults.
Journal ArticleDOI
Addition of dose-intensified doxorubicin to standard chemotherapy for rhabdomyosarcoma (EpSSG RMS 2005): a multicentre, open-label, randomised controlled, phase 3 trial
Gianni Bisogno,Meriel Jenney,Christophe Bergeron,Soledad Gallego Melcon,Andrea Ferrari,Odile Oberlin,Modesto Carli,Michael C. Stevens,Anna Kelsey,Angela De Paoli,Mark N. Gaze,Hélène Martelli,Christine Devalck,Johannes H. M. Merks,Myriam Weyl Ben‐Arush,Heidi Glosli,Julia C. Chisholm,Daniel Orbach,Veronique Minard-Colin,Gian Luca De Salvo,Maja Cesen,Adriana Rose,Sima Ferman,Peter Múdry,Daniela Sejnová,Paola Dal Bianco,Ilaria Zanetti,Felix Niggli,Timothy Rogers,Giovanni Cecchetto,Federica De Corti,Florent Guérin,Sheila Terwisscha,Dominique Ranchère,Rita Alaggio,Janet Shipley,Angelo Rosolen,H. Mandeville,Giovanni Scarzello,Valérie Bernier,Kieran McHugh +40 more
TL;DR: The possible benefit of early dose intensification with doxorubicin in patients with non-metastatic rhabdomyosarcoma was evaluated, and patients who received at least one dose of study treatment were considered in the safety analysis.